Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells

Journal of Proteomics

Volumn 75, Issue 18, 2012, Pages 5822-5847

  Lin, Szu Ting ^a   Chou, Hsiu Chuan ^a   Chang, Shing Jyh ^b,c   Chen, Yi Wen ^a   Lyu, Ping Chiang ^a   Wang, Wen Ching ^a   Chang, Margaret Dah Tsyr ^a   Chan, Hong Lin ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

Author keywords

DIGE; Doxorubicin; MALDI TOF; Proteomics; Resistance; Uterine cancer

Indexed keywords

ASPARTATE AMMONIA LIGASE; DOXORUBICIN; MEMBRANE ASSOCIATED PROGESTERONE RECEPTOR COMPONENT 1; PROGESTERONE RECEPTOR; PROTEOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENCY; FUNCTIONAL PROTEOMICS; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UTERUS CANCER;

APOPTOSIS; ASPARTATE-AMMONIA LIGASE; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTEOMICS; RECEPTORS, PROGESTERONE; SARCOMA; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UTERINE NEOPLASMS;

EID: 84866148089     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.047     Document Type: Article

References (44)

1. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65:3145-3167.
2. Verma S., Dent S., Chow B.J., Rayson D., Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008, 34:391-406.
3. Vatsyayan R., Chaudhary P., Lelsani P.C., Singhal P., Awasthi Y.C., Awasthi S., et al. Role of RLIP76 in doxorubicin resistance in lung cancer (review). Int J Oncol 2009, 34:1505-1511.
4. Green A.E., Rose P.G. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine 2006, 1:229-239.
5. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008, 7:670-678.
6. Harisi R., Dudas J., Nagy-Olah J., Timar F., Szendroi M., Jeney A. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function. Cancer Biol Ther 2007, 6:1240-1246.
7. Ferreira M.J., Duarte N., Gyemant N., Radics R., Cherepnev G., Varga A., et al. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res 2006, 26:3541-3546.
8. Song X., Liu X., Chi W., Liu Y., Wei L., Wang X., et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006, 58:776-784.
9. Biing J.T., Yang Y.F., Liu H.S., Ye C.T., Chao C.F. The induction of multidrug resistance in human cervical carcinoma cell lines by estrogenic hormones. Proc Natl Sci Counc Repub China B 1994, 18:64-70.
10. Timms J.F., Cramer R. Difference gel electrophoresis. Proteomics 2008, 8:4886-4897.
11. Lai T.C., Chou H.C., Chen Y.W., Lee T.R., Chan H.T., Shen H.H., et al. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res 2010, 9:1302-1322.
12. Chou H.C., Chen Y.W., Lee T.R., Wu F.S., Chan H.T., Lyu P.C., et al. Proteomics study of oxidative stress and Src kinase inhibition in H9C2 cardiomyocytes: a cell model of heart ischemia reperfusion injury and treatment. Free Radic Biol Med 2010, 49:96-108.
13. Wu C.L., Chou H.C., Cheng C.S., Li J.M., Lin S.T., Chen Y.W., et al. Proteomic analysis of UVB-induced protein expression- and redox-dependent changes in skin fibroblasts using lysine- and cysteine-labeling two-dimensional difference gel electrophoresis. J Proteomics 2012, 75:1991-2014.
14. Harker W.G., Sikic B.I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 1985, 45:4091-4096.
15. Harker W.G., MacKintosh F.R., Sikic B.I. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 1983, 43:4943-4950.
16. Noh D.Y., Ahn S.J., Lee R.A., Kim S.W., Park I.A., Chae H.Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 2001, 21:2085-2090.
17. Torosyan Y., Simakova O., Naga S., Mezhevaya K., Leighton X., Diaz J., et al. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells. Int J Cancer 2009, 125:2528-2539.
18. Tu S.H., Chang C.C., Chen C.S., Tam K.W., Wang Y.J., Lee C.H., et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2010, 121:539-553.
19. Bonfils C., Bec N., Larroque C., Del Rio M., Gongora C., Pugniere M., et al. Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c. Biochem Biophys Res Commun 2010, 393:325-330.
20. Zhang D., Putti T.C. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. Exp Cell Res 2010, 316:3522-3531.
21. Injac R., Strukelj B. Recent advances in protection against doxorubicin-induced toxicity. Technol Cancer Res Treat 2008, 7:497-516.
22. Kotamraju S., Kalivendi S.V., Konorev E., Chitambar C.R., Joseph J., Kalyanaraman B. Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol 2004, 378:362-382.
23. Taatjes D.J., Fenick D.J., Gaudiano G., Koch T.H. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Curr Pharm Des 1998, 4:203-218.
24. Srivastava R.K., Sasaki C.Y., Hardwick J.M., Longo D.L. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med 1999, 190:253-265.
25. Yung B.Y., Busch H., Chan P.K. Translocation of nucleolar phosphoprotein B23 (37kDa/pI 5.1) induced by selective inhibitors of ribosome synthesis. Biochim Biophys Acta 1985, 826:167-173.
26. Chang J.H., Olson M.O. Structure of the gene for rat nucleolar protein B23. J Biol Chem 1990, 265:18227-18233.
27. Szebeni A., Herrera J.E., Olson M.O. Interaction of nucleolar protein B23 with peptides related to nuclear localization signals. Biochemistry 1995, 34:8037-8042.
28. Szebeni A., Olson M.O. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999, 8:905-912.
29. Kondo T., Minamino N., Nagamura-Inoue T., Matsumoto M., Taniguchi T., Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 1997, 15:1275-1281.
30. Lee H.J., Oh Y.K., Rhee M., Lim J.Y., Hwang J.Y., Park Y.S., et al. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol 2007, 369:967-984.
31. Kuramitsu Y., Taba K., Ryozawa S., Yoshida K., Zhang X., Tanaka T., et al. Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 2010, 30:3367-3372.
32. Takayama S., Krajewski S., Krajewska M., Kitada S., Zapata J.M., Kochel K., et al. Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res 1998, 58:3116-3131.
33. Hsu H.S., Lin J.H., Huang W.C., Hsu T.W., Su K., Chiou S.H., et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011, 117:1516-1528.
34. Concannon C.G., Orrenius S., Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 2001, 9:195-201.
35. Cho J.H., Song H.O., Singaravelu G., Sung H., Oh W.C., Kwon S., et al. Pleiotropic roles of calumenin (calu-1), a calcium-binding ER luminal protein, in Caenorhabditis elegans. FEBS Lett 2009, 583:3050-3056.
36. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
37. Wu W., Tang X., Hu W., Lotan R., Hong W.K., Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002, 19:319-326.
38. Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011, 2:380.
39. Cahill M.A. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007, 105:16-36.
40. Neubauer H., Adam G., Seeger H., Mueck A.O., Solomayer E., Wallwiener D., et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009, 12:230-239.
41. Yang T., Espenshade P.J., Wright M.E., Yabe D., Gong Y., Aebersold R., et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002, 110:489-500.
42. Peluso J.J., Pappalardo A., Losel R., Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006, 147:3133-3140.
43. Neubauer H., Clare S.E., Wozny W., Schwall G.P., Poznanovic S., Stegmann W., et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10:R85.
44. Cui H., Darmanin S., Natsuisaka M., Kondo T., Asaka M., Shindoh M., et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res 2007, 67:3345-3355.